Dorothy Dulko, PhD, on Social Determinants of Developing Colorectal Cancer

Video

During Colorectal Cancer Awareness month, CancerNetwork® sat down with Dorothy Dulko, PhD, to discuss social determinants of cancer.

To continue recognition of Colorectal Cancer Awareness month, CancerNetwork® sat down with Dorothy Dulko, PhD, APRN-C, AOCNP, WHNP-BC, OB/GYN-NP, CCRP, faculty member for Walden University’s Master of Science in Nursing program, to discuss factors that go into determining cancer disparities.

“One of the most important pieces when describing disparities is something called social determinants of health,” Dulko said. “Some of these social determinants [include] how we live, where we are born, where we work, where we play, where we worship, and our age.”

Dulko went on to say that rates of colorectal cancer, as well as lung and cervical cancers, are higher in places like rural Appalachia as compared with urban areas in the same region. And this, as well as other health disparities, are attributable to patient education levels. In addition, patients with more financial support tend to have better outcomes with their disease as compared with their counterparts with less financial support.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences™ Medical World News®, airing daily on all MJH Life Sciences™ channels.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Treatment with KRAS inhibitors may help mitigate a common driver of genetic alteration across a majority of pancreatic cancers.
Updated results from the BREAKWATER study seemed to be most impactful to the CRC space, according to Michael J. Pishvaian, MD, PhD.
Future research will aim to assess the efficacy of PIPAC-MMC plus systemic therapy vs systemic therapy alone in patients with peritoneal tumors.
Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.
Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.
Combining sotorasib with panitumumab may reduce the burden of disease in patients with KRAS G12C-mutated metastatic colorectal cancer.
Findings from the CodeBreak 300 study have cemented sotorasib/panitumumab as a third-line treatment option for KRAS G12C-mutated colorectal cancer.
Sotorasib plus panitumumab may offer improved survival compared with previously approved treatment options in KRAS G12C-mutated colorectal cancer.
Additional local, regional, or national policy may bolster access to screening for colorectal cancer, according to Aasma Shaukat, MD, MPH.
Related Content